Trial Profile
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors GSK
- 31 May 2011 New trial record